Skip to main content

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Publication ,  Journal Article
Earl, PL; Sugiura, W; Montefiori, DC; Broder, CC; Lee, SA; Wild, C; Lifson, J; Moss, B
Published in: J Virol
January 2001

The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHIV-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

January 2001

Volume

75

Issue

2

Start / End Page

645 / 653

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Virus Replication
  • Virology
  • Vaccination
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Simian Acquired Immunodeficiency Syndrome
  • Rabbits
  • Peptide Fragments
  • Neutralization Tests
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Earl, P. L., Sugiura, W., Montefiori, D. C., Broder, C. C., Lee, S. A., Wild, C., … Moss, B. (2001). Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol, 75(2), 645–653. https://doi.org/10.1128/JVI.75.2.645-653.2001
Earl, P. L., W. Sugiura, D. C. Montefiori, C. C. Broder, S. A. Lee, C. Wild, J. Lifson, and B. Moss. “Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.J Virol 75, no. 2 (January 2001): 645–53. https://doi.org/10.1128/JVI.75.2.645-653.2001.
Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol. 2001 Jan;75(2):645–53.
Earl, P. L., et al. “Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.J Virol, vol. 75, no. 2, Jan. 2001, pp. 645–53. Pubmed, doi:10.1128/JVI.75.2.645-653.2001.
Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol. 2001 Jan;75(2):645–653.

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

January 2001

Volume

75

Issue

2

Start / End Page

645 / 653

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Virus Replication
  • Virology
  • Vaccination
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Simian Acquired Immunodeficiency Syndrome
  • Rabbits
  • Peptide Fragments
  • Neutralization Tests